1-10 of 10
Marc Y. Donath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154

Beckey Trinh, Marc Y. Donath, Heinz Läubli
Journal: Diabetes Care
Diabetes Care 2020;43(1):e11
https://doi.org/10.2337/dci19-0058
Published: 12 December 2019
View article titled, Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154
Open the PDF for Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154 in another window
Journal Articles

Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab

Beckey Trinh, Marc Y. Donath, Heinz Läubli
Journal: Diabetes Care
Diabetes Care 2019;42(9):e153–e154
https://doi.org/10.2337/dc19-0908
Published: 15 July 2019
View article titled, Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab
Open the PDF for Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab in another window
Journal Articles

Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications

Rena M. Pollack, Marc Y. Donath, Derek LeRoith, Gil Leibowitz
Journal: Diabetes Care
Diabetes Care 2016;39(Supplement_2):S244–S252
https://doi.org/10.2337/dcS15-3015
Published: 16 July 2016
View article titled, Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Open the PDF for Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications in another window
Journal Articles

GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?

Marc Y. Donath, MD, Rémy Burcelin, PHD
Journal: Diabetes Care
Diabetes Care 2013;36(Supplement_2):S145–S148
https://doi.org/10.2337/dcS13-2015
Published: 17 July 2013
View article titled, GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?
Open the PDF for GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine? in another window
Journal Articles

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes

Katharina Timper, MD, Petr Hruz, MD, Christoph Beglinger, MD, Marc Y. Donath, MD
Journal: Diabetes Care
Diabetes Care 2013;36(7):e90–e91
https://doi.org/10.2337/dc13-0199
Published: 12 June 2013
View article titled, Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
Open the PDF for Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes in another window
Journal Articles

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

Claudia Cavelti-Weder, MD, Andrea Babians-Brunner, MD, Cornelia Keller, MD, Marc A. Stahel, MD, Malaika Kurz-Levin, MD, Hany Zayed, PHD, Alan M. Solinger, MD, Thomas Mandrup-Poulsen, MD, Charles A. Dinarello, MD, Marc Y. Donath, MD
Journal: Diabetes Care
Diabetes Care 2012;35(8):1654–1662
https://doi.org/10.2337/dc11-2219
Published: 14 July 2012
View article titled, Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Open the PDF for Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy

Claudia Cavelti-Weder, MD, Bettina Muggli, MD, Cornelia Keller, MD, Andrea Babians-Brunner, MD, Anna Biason-Lauber, MD, Marc Y. Donath, MD, Peter Schmid-Grendelmeier, MD
Journal: Diabetes Care
Diabetes Care 2012;35(6):e41
https://doi.org/10.2337/dc12-0115
Published: 11 May 2012
View article titled, Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy
Open the PDF for Successful Use of Omalizumab in an Inadequately Controlled Type 2 Diabetic Patient With Severe Insulin Allergy in another window
Journal Articles

Inhibition of IL-1 β Improves Fatigue in Type 2 Diabetes

Claudia Cavelti-Weder, MD, Romana Furrer, MD, Cornelia Keller, MD, Andrea Babians-Brunner, MD, Alan M. Solinger, MD, H. Gast, MD, A. Fontana, MD, Marc Y. Donath, MD, Iris K. Penner, PHD
Journal: Diabetes Care
Diabetes Care 2011;34(10):e158
https://doi.org/10.2337/dc11-1196
Published: 15 September 2011
View article titled, Inhibition of IL-1 β Improves Fatigue in Type 2 Diabetes
Open the PDF for Inhibition of IL-1 β Improves Fatigue in Type 2 Diabetes in another window
Journal Articles

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

Claus M. Larsen, MD, Mirjam Faulenbach, MD, Allan Vaag, MD, PHD, Jan A. Ehses, PHD, Marc Y. Donath, MD, Thomas Mandrup-Poulsen, MD, PHD
Journal: Diabetes Care
Diabetes Care 2009;32(9):1663–1668
https://doi.org/10.2337/dc09-0533
Published: 19 June 2009
View article titled, Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Open the PDF for Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Islet Inflammation in Type 2 Diabetes: From metabolic stress to therapy

Marc Y. Donath, MD, Desiree M. Schumann, PHD, Mirjam Faulenbach, MD, Helga Ellingsgaard, PHD, Aurel Perren, MD, Jan A. Ehses, PHD
Journal: Diabetes Care
Diabetes Care 2008;31(Supplement_2):S161–S164
https://doi.org/10.2337/dc08-s243
Published: 01 February 2008
View article titled, Islet Inflammation in Type 2 Diabetes: <subtitle>From metabolic stress to therapy</subtitle>
Open the PDF for Islet Inflammation in Type 2 Diabetes: <subtitle>From metabolic stress to therapy</subtitle> in another window